FAL Lawyers
Menu
Home Our People Legal Services Intellectual Property Industry Expertise News & Resources Contact Us
Back to Resources

Monsoon Communications Investor Twilight Briefing

You are invited

Monsoon Communications Investor Twilight Briefing

monsoon logo.jpg

 

Thursday 5 March 2015
4.15pm for 4.30pm (sharp) start

Level 12, 15 William Street, Melbourne

These three 15 min company briefings to ~5:15pm when canapés and drinks will be served


Briefings from

 

4.30pm – Dr Kilian Kelly, VP Product Development – Cynata Therapeutics (ASX:CYP)

- World first stem cell manufacturing technology Cymerus™

- Enables large scale, low cost stem cell production for the first time

- Global demand for stem cell therapies to treat diseases including diabetes, stroke, heart disease

- Japanese Government to allow stem cell products to market after Phase 2 development
 


4.45pm – Dr Richard Hopkins, CEO – Phylogica (ASX:PYC)

- Recent USD142m license agreement with Genentech in search for antibiotics to fight superbugs

- Genentech deal – second largest deal by ASX-listed biotech in 2014

- Recent data confirms PYC cell penetrating peptides are best-in-class for delivering biologics drugs inside cells

- Accelerating oncology program


5pm – Dr Greg Collier, Managing Director & CEO – Invion (ASX:IVX)

- 3 drug candidates targeting respiratory and autoimmune diseases with large unmet need e.g. asthma, COPD, cystic fibrosis


- Excellent recent phase II interim data for INV102 (nadolol) shows clinically significant effect on inflammatory markers


- Global respiratory franchise partners include 3M


- Key milestones in five programs expected over next 6-12 months

 

RSVP by 4 March 2015 to Matthew Wright at
Monsoon Communications on 03 9620 3333 or

mattheww@monsoon.com.au


Proudly sponsored by FAL Lawyers

FAL Lawyers logo (2).jpg